The analysis of TCGA BLCA patient datasets revealed that a single nucleotide polymorphism, rs1014971, but not the germline A3A/A3B deletion [36], was associated with BLCA risk, increased A3B expression and enrichment with APOBEC-signature mutations in bladder tumours (figure 5). Here, APOBEC3B is linked to urinary bladder neoplasm.